Telum Therapeutics, founded in 2019, is developing protein-based antimicrobial therapies using its proprietary APEX platform. Its lead programme targets severe infections caused by Acinetobacter baumannii, specifically hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The company plans to use the Series A proceeds to complete Phase 1 clinical development of the lead candidate and to advance its broader pipeline against both Gram-negative and Gram-positive pathogens. Telum positions its approach as potentially overcoming limitations of existing antibiotic treatments. No revenue, user, or other operating metrics were disclosed in the announcement. The company highlighted support from both public and private Spanish and international investors as part of its financing.

Total raised

$21M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2026